Search PubMed⌕ Search

Biomedical subjects

C H Li

Publications and source records attributed to C H Li.

At least 127 records · Page 7Linked to original sources

Characterization of solubilized human and rat brain beta-endorphin-receptor complex.

Opioid receptors have been solubilized from human striatal and rat whole-brain membranes by use of 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). Tritiated human beta-endorphin (3H-beta h-EP) binding revealed high-affinity competition by morphine, naloxone, and various beta-EP analogues, suggesting predominantly mu-type binding. Lack of high-affinity competition by (+/-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneaceta mide methanesulfonate (U50-488, Upjohn) indicated that kappa sites were not labeled by 3H-beta h-EP under these conditions. Affinities were similar in both soluble and membrane preparations except for [Met]enkephalin, which appears to be rapidly degraded by the solubilized extract. Size differences between human and rat solubilized 3H-beta h-EP-receptor complexes were revealed by exclusion chromatography.

Adolescent↗

Human seminal alpha-inhibins: detection in human pituitary, hypothalamus, and serum by immunoreactivity.

An antiserum generated in rabbits against human seminal alpha-inhibin-52 has been used to develop a sensitive radioimmunoassay for the detection of alpha-inhibins. The alpha-inhibin-52 antiserum reacts with alpha-inhibin-92 and alpha-inhibin-31 with equal avidity. These peptides were found to be present in human pituitary, hypothalamus, and serum. In exclusion chromatography on Sephadex G-100, the immunoreactive material eluted in a large molecular size region. Immunoblot analysis of column-derived fractions of these extracts revealed the presence of alpha-inhibin-92. The mean concentrations of immunoreactive alpha-inhibin were found to be 7.2 ng/ml in normal adult male serum, 70.3 ng/g (wet weight) of pituitary, and 12.9 ng/g (wet weight) of hypothalamus. This communication reports on the evidence for the existence of gonadal peptides in the brain.

Humans↗

Preparation of [125I-Tyr27,Leu5]beta h-endorphin and its use for crosslinking of opioid binding sites in human striatum and NG108-15 neuroblastoma-glioma cells.

A radioligand suitable for crosslinking studies to opioid receptors has been obtained by radioiodination and purification of the monoiodotyrosine-27 derivative of the synthetic human beta-endorphin (beta h-endorphin) analogue [5-leucine]beta h-endorphin. The derivative, [27-[125I]monoiodotyrosine,5-leucine]beta h-endorphin, was crosslinked to human striatal (caudate and putamen) and NG108-15 neuroblastoma-glioma cell membranes by using disuccinimidyl suberate. Sodium dodecyl sulfate/polyacrylamide gel electrophoresis under reducing conditions revealed four specifically labeled bands at 68, 40, 30, and 25 kDa for both human caudate and putamen, whereas NG108-15 cell membranes gave specifically labeled bands at 92, 56, 38, and 23 kDa.

Adult↗

beta-Endorphin-(1-27) inhibits the spinal beta-endorphin-induced release of Met-enkephalin.

The effect of intraventricular beta-endorphin-(1-27) on the spinal release of Met-enkephalin induced by intraventricular beta-endorphin was studied using the intrathecal superfusion technique in urethane anesthetized rats. Intraventricular injection of beta-endorphin at a dose of 15 micrograms released Met-enkephalin from the spinal cord. This release of Met-enkephalin induced by beta-endorphin was significantly reduced by beta-endorphin-(1-27), 60 micrograms, injected intraventricularly. Injection of beta-endorphin (1-27) itself did not cause any release of Met-enkephalin. The finding is in line with the previous report that beta-endorphin (1-27) inhibited the analgesia induced by beta-endorphin.

Animals↗

Chemical synthesis of alpha-inhibin-92 by the thiocarboxyl segment coupling method.

The amino acid residue peptide, alpha-inhibin-92 (alpha-IB-92), has been synthesized by the thiocarboxyl segment strategy. Three segments were synthesized by the solid phase method, purified, and characterized: [GlyS34]-alpha-IB-92-(1-34) (I), CF3CO-[GlyS65]-alpha-IB-92-(35-65) (II), and Msc-alpha-IB-92-(66-92) (III). All were reacted with citraconic anhydride followed by removal of the Msc group in III to give Ia, IIa, and IIIa, respectively. Peptide IIIa was coupled to IIa by the silver nitrate/N-hydroxysuccinimide procedure and, after removal of uncoupled segments and the trifluoroacetyl group, Ia was coupled followed again by removal of uncoupled segments. Final deblocking to remove citraconyl groups was accomplished under exceptionally mild conditions in aqueous acetic acid. The synthetic product was identical to natural alpha-IB-92 in amino acid analysis, HPLC, gel electrophoresis, and tryptic mapping. The synthetic peptide was indistinguishable from natural alpha-IB-92 in a radioimmunoassay and in an in vitro mouse pituitary assay for measuring suppression of FSH release in the presence of LHRH.

Amino Acid Sequence↗

beta-Endorphin: intranasal administration increases the serum prolactin level in monkey.

Human beta-endorphin has been administered by nasal spray technique at a dose of 0.02 mg per kg in female bonnet monkeys. A significant increase of serum prolactin levels was observed within 30 min and maintained up to 60 min. In the same dose, intravenous injections of the hormone caused a marginal increase of prolactin levels only after 60 min. It was concluded that administration of beta-endorphin by nasal spray is more effective than the intravenous injection.

Administration, Intranasal↗

Dose-related effects of synthetic human beta-endorphin and naloxone on fed gastrointestinal motility.

In humans, plasma beta-endorphin levels rise during application of acute stressful stimuli (vertigo, cold pain, and transcutaneous electrical stimulation) that induce gut motor disturbances. Whereas it is possible that circulating beta-endorphin participates in the mediation of these central effects on gut motility, its role cannot be established solely on the basis of changes in plasma levels. Therefore, we designed the present study to investigate 1) the dose-related effects of intravenous synthetic human beta-endorphin and naloxone on gastrointestinal pressure activity in fed healthy individuals; and 2) the interactions of the opiate agonist and antagonist. Infusion of beta-endorphin increased pyloric phasic pressure activity (P less than 0.001) and induced intestinal bursts of rhythmic activity (P less than 0.05) which interrupted normal fed motility. These effects were dose related, with the pyloric dose-response profile being essentially linear. The effects in the proximal intestine were obtained with doses of beta-endorphin at 250 ng X kg-1 X min-1 or greater. In the antrum, there was an overall reduction in phasic pressure activity (P less than 0.02), which was predominantly an effect of the highest dose of beta-endorphin infused (2,500 ng X kg-1 X min-1). Naloxone by itself had no significant effect on fed upper gut motility. However, naloxone significantly inhibited the effect of the lower doses of beta-endorphin on the pylorus. In addition, naloxone significantly reduced the probability of beta-endorphin, triggering intestinal bursts of rhythmic activity. These data suggest that beta-endorphin may play a humoral role in the stimulation of fed pyloric contraction at physiological levels.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗

Specific insulin-like growth factor (IGF) I- and II-binding sites on rat granulosa cells: relation to IGF action.

Although insulin-like growth factor-I (IGF-I) and insulin have been shown to augment rat granulosa cell differentiation, their mechanism(s) of action has not yet been elucidated. In the present study, we have examined granulosa cells obtained from immature hypophysectomized estrogen-treated rats for specific IGF-binding sites that might mediate the effects of the insulin-like peptides. Using synthetic [125I]iodo-IGF-I, we have found specific high affinity, low capacity (Kd = 1.36 +/- 0.131 nM; 3250 +/- 662 sites/cell) IGF-I-binding sites that have lower affinities for the related peptides IGF-II and insulin (potency ratio, 1:9:700 for IGF-I, IGF-II, and insulin). We have also found specific binding sites for [125I]iodo-IGF-II, a newly available synthetic peptide. The IGF-II-preferring sites were of a single class (Kd = 1.54 +/- 0.32 nM; 4728 sites/cell) and exhibited a rank competition order of IGF-II greater than IGF-I much greater than insulin. To study the functional correlates of these binding activities, granulosa cells were cultured for 2 days in serum-free medium in the presence of FSH, with or without increasing concentrations of IGF-I, IGF-II, or insulin. Medium steroids were then determined by specific RIA, and cellular LH/hCG receptors were measured by specific [125I]iodo-hCG binding. Treatment with FSH increased estrogen and progestin production and induced the formation of LH/hCG receptors. Concomitant treatment with the three peptides dose-dependently enhanced both FSH-stimulated steroidogenesis and LH/hCG receptor induction, with a rank order of potency of IGF-I greater than IGF-II greater than insulin (potency ratio, 1:8:36). This rank order of potency of the insulin-like peptides was more closely correlated with their ability to compete for IGF-I binding rather than IGF-II binding, suggesting the preferential involvement of IGF-I receptors in the ovarian actions of the IGFs, although the involvement of IGF-II and insulin receptors cannot be dismissed. Our results demonstrate, for the first time, a biological action of synthetic IGF-II in granulosa cells and further show a novel insulin effect, enhancement of LH/hCG receptor induction. These findings also indicate that rat granulosa cells possess specific IGF-I and IGF-II-binding sites that may mediate the gonadotropin-enhancing actions of the insulin-like peptides. Since IGF-I appears to be the most biologically potent peptide, it is likely to be the most important insulin-like peptide involved in granulosa cell differentiation in vivo.

Animals↗

Beta-endorphin attenuates the serum cortisol response to exogenous adrenocorticotropin.

Controversy surrounds the issue of whether beta-endorphin affects adrenal steroidogenesis. Recent work has both supported and refuted the claim that beta-endorphin stimulates a rise in serum aldosterone. We investigated the role of beta-endorphin in adrenal steroidogenesis by examining its potential modulation of the response of serum cortisol to exogenous ACTH (Cosyntropin). Four of five normal men received: 1) synthetic beta-endorphin (1 microgram/kg X min) for 30 min, followed by a bolus dose of 0.2 micrograms ACTH; 2) beta-endorphin (100 micrograms, iv), followed by 0.2 micrograms ACTH iv; 3) 0.2 micrograms ACTH iv; and 4) beta-endorphin (100 micrograms iv) alone. The integrated cortisol response to exogenous ACTH, calculated as the area under the cortisol response curve, was significantly less when the ACTH infusion was preceded by the 30-min beta-endorphin infusion than when administered alone [163 +/- 50 (SE) microgram/dl X min vs. 282 +/- 51 micrograms/dl X min, respectively; P less than 0.01]. By contrast, there was no difference between the integrated cortisol response to exogenous ACTH alone and exogenous ACTH after the bolus dose of beta-endorphin (282 +/- 51 vs. 293 +/- 39 micrograms/dl X min, respectively). Beta-Endorphin (30-min infusion or 100-micrograms bolus dose alone) caused no change in serum aldosterone, dehydroepiandrosterone, or PRA. Serum PRL levels, however, were raised significantly (P less than 0.05) by the 30-min infusion of beta-endorphin. The infusion and bolus doses of beta-endorphin raised plasma beta-endorphin levels to over 100,000 pg/ml and 5,000 pg/ml, respectively. We conclude that very high plasma levels of beta-endorphin may influence the response of cortisol to ACTH through a direct effect on the adrenal cortex. However, even in disease states such as Addison's and Nelson's diseases, such levels of plasma beta-endorphin are not known to be achieved.

Adrenocorticotropic Hormone↗

Structure-function studies on human growth hormone. Evidence that tertiary structure is essential for biological activity.

The relationship between the conformation of human pituitary growth hormone (hGH), biological activity, and ligand binding activity was studied by comparing conformational details previously published on in vivo and in vitro studies of identical samples of hGH and its known derivatives. In vivo assays included the rat tibia test for somatotropic activity and the pigeon crop-sac assay for lactogenic hormone activity. Relative binding affinities were compared in radioimmunoassays using 125I-hGH as tracer with 1) anti-human chorionic somatomammotropin (hCS) serum (low discriminatory hybrid assay), 2) anti-hGH sera (in conventional assays), 3) monospecific anti-hGH serum (absence of cross-reaction with hCS) and 4) human anti-hGH sera obtained from GH-deficient patients on replacement therapy. In addition, binding affinities were examined in two receptor-binding assays, one specific for somatotropic activity (rabbit liver membranes, 125I-hGH), and the other, for lactogenic hormones (rabbit mammary membranes, 125I-oPRL). The conformational properties of native hGH and various chemically and enzymatically modified derivatives of the hormone were evaluated primarily from circular dichroism spectra, while conformational stabilities were estimated from the relative rates of tryptic digestion. Unfragmented, but chemically modified derivatives, exhibited good parallelism between retention or loss of native conformation and the in vivo potencies and in vitro binding affinities. None of the fragments of hGH showed activity in any of the radioreceptor assays or radioimmunoassays. Two derivatives of hGH, which contain gaps of 6 or 12 residues in the polypeptide backbone produced by partial enzymatic digestion, had full or increased in vivo potencies, full activities in the radioimmunoassays, and were the most active derivatives in both radioreceptor assays. One of these, missing the hexapeptide corresponding to residues 135-140, was also found to retain nearly all the conformational properties of native hGH. These studies proved further evidence that 1) retention by modified forms of hGH of a high degree of in vivo biological potency or in vitro binding affinity is causally related to the retention of most of the conformation and conformational stability of the molecule, and 2) the biologically active, receptor-binding and immunoreactive sites on the hGH molecule are 3-dimensional in nature.

Animals↗

Tertiary structure in deletion analogues of human beta-endorphin: resistance to leucine aminopeptidase action.

The presence of tertiary structure in aqueous solutions of the amino-terminal nine- and seventeen-residue analogues of human beta-endorphin has been further demonstrated by leucine aminopeptidase (LAP) cleavage of the amino-terminal tyrosine. The reactions were followed by difference absorption spectroscopy. While the amino-terminal pentapeptide showed no resistance to LAP action, the nonapeptide displayed definite resistance. The heptadecapeptide analogue was found to be completely refractory to LAP action under the conditions employed. Thermolysin cleavage of the Phe4-Met5 bond in the longer analogues destroys the tertiary structure, not only removing the previously reported red shift in tyrosine absorption but also resulting in complete normalization to LAP digestion.

Endorphins↗

Beta-endorphin: photoaffinity labelling of a non-opioid binding site in a human neuroblastoma.

A photoaffinity reagent 2-nitro-4-azidophenylsulfenyl chloride (2,4-NAPS-Cl) and synthetic analogs of human beta-endorphin (beta h-EP) were employed to demonstrate the presence of receptor sites specific for beta h-EP but of non-opioid character in a human neuroblastoma cell line (IMR-32). The radioactive photoaffinity probe was carried out using [125I-Tyr1,2,4-NAPS-Trp27]-beta h-EP and IMR-32 cell membranes. After solubilization with sodium dodecyl sulfate (SDS) and SDS polyacrylamide gel electrophoresis, a single labelled protein band was identified with a molecular weight of 72,000. Labelling was blocked by beta h-EP or beta h-EP-(6-31) but remained in the presence of beta h-EP-(1-27). The specificity of this band is thus identical to that of the non-opioid site previously characterized. Various nonionic or zwitterionic detergents did not extract the labelled non-opioid site.

Affinity Labels↗

Human somatotropin: noncovalent interactions of the natural NH2-terminal 1-134 segment with synthetic analogs of the COOH-terminal fragment.

Three analogs of the COOH-terminal fragments of human somatotropin (HGH), namely [Nle170,Ala165,182]-HGH-(150-187), [Nle170,Ala165,182]-HGH-(152-187), and [Nle170,Ala165,182]-HGH-(154-187), have been synthesized by the solid-phase method. The synthetic analogs were complemented with the natural NH2-terminal fragment [Cys(Cam)53]-HGH-(1-134) to form recombinants with HGH activities, as revealed by the rabbit liver membrane receptor binding and the Nb2 lymphoma cell assays.

Amino Acid Sequence↗

Opiate receptor binding profile in the rabbit cerebellum and brain membranes.

The equilibrium dissociation constants (Kd) and maximal binding capacities of tritiated dihydromorphine (DHM), [D-Ala2,D-Leu5]enkephalin (DADLE), ethylketocyclazocine (EKC) and human beta-endorphin (beta-EP) in rabbit cerebellum and brain membranes have been investigated. Binding of tritiated DHM and DADLE was adequately described by a single affinity class of binding sites, while that of EKC required two affinity sites. Binding of tritiated beta-EP was also consistent with a single affinity class of binding sites by Scatchard analysis, but inhibition of the binding with type selective opiate receptor ligands revealed multiple sites. Sequential displacement of a broad spectrum opiate ligand, diprenorphine (DIP), by type selective ligands showed that cerebellum membranes are relatively rich in mu (40%) and deficient in K (12%) binding sites, while brain membranes are relatively rich in K (32%) and deficient in mu (12%) binding sites. beta-EP displaces 88 and 73% of tritiated DIP from cerebellum and brain membranes, respectively, suggesting multiple sites of beta-EP binding.

Animals↗

Synthetic insulin-like growth factor II.

Human insulin-like growth factor II with 67 amino acid residues and three disulfide bridges has been synthesized by the solid-phase method. Homogeneity of the synthetic product is ascertained by chromatofocusing, high performance liquid chromatography and amino acid analysis. In both radioimmunoassay and radioreceptor assay, the synthetic product is indistinguishable from the natural hormone.

Amino Acids↗

Inhibition of analgesia by C-terminal deletion analogs of human beta-endorphin.

Human beta-endorphin (beta h-EP) analogs of variable chain lengths have been investigated for their potency in inhibiting analgesia induced by beta h-EP or by the potent opiate etorphine. It was found that beta h-EP-(1-28) inhibits the analgesic effect of beta h-EP and etorphine when co-injected intracerebroventricularly into mice. Antagonism by competition at same opioid receptor subtypes is suggested from parallel shifts of the dose-response curve of etorphine or beta h-EP in the presence of increasing doses of beta h-EP-(1-28). On a molar basis, beta h-EP-(1-28) is nearly 10 times more potent than naloxone. The reduction of the chain length from residues 1-28 to 1-27 lowered the antagonist potency while further reduction of the peptide chain led to a complete loss of inhibitory activity. From comparison of the opioid-receptor binding affinity, analgesic activity and antagonist potency, it is concluded that the C-terminus of beta-EP is critical to the biological efficacy of the molecule and that the antagonist activity of C-terminal deletion analogs is probably mediated through residues 27 and 28.

Analgesics↗